Longtime MSNBC host Rachel Maddow sounded off during a Monday night broadcast of “The Rachel Maddow Show” on the network’s ...

Hims & Hers projects $725M in GLP-1 weight loss revenue for 2025, a 3.2x increase from 2024. Read why I upgrade HIMS stock ...

Some health experts have call for further investigation, as figures show 82 deaths with suspected links to slimming drugs ...

After the FDA removed semaglutide injection products from a shortage list, compounders like Hims have 60-90 days to stop ...

Pfizer appoints Patrizia Cavazzoni as chief medical officer, the U.S. delays the definition of 'healthy' on labels, issues ...

The lawsuit claims the FDA's finding that there was no longer a shortage of the drugs' active ingredient semaglutide was ...

Hims & Hers Health (HIMS) has seen its shares decline over 17% in the past week since the U.S. Food and Drug Administration (FDA) announced ...

Ozempic and its contemporaries are the new craze. But would you believe it when we say that these weight-loss drugs would be ...

Telehealth and wellness platform Hims & Hers on Monday offered a revenue outlook for the year ahead that topped Wall Street's expectations, but shares fell hard in after-hours trading, in an echo of ...

The shortage of Ozempic and Wegovy has been declared over by the Food and Drug Administration, a change that suggests higher ...

Weight loss drugs quickly became the go-to tactic for celebrities like Fat Joe, Kathy Bates, Macy Gray, Kelly Clarkson, Rebel ...

On Friday, the US Food and Drug Administration announced drugs Wegovy and Ozempic by Novo Nordisk are no longer in shortage.